EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-World Implementation of Molecular Testing and Biomarker-Guided Therapies in HR+/HER2− Metastatic Breast Cancer

Christine Deutschmann, Matthias Filipovic, Dagmar Baha, Leonhard Müllauer iD, Zsuzsanna Bago-Horvath, Daphne Gschwantler-Kaulich, Georg Pfeiler, Carmen Leser iD, Christian F Singer iD

Cancers · 28.10.2026 · 18 (21) · 3482

DOI: 10.3390/cancers18213482 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 28.10.2026. Verfasst von Christine Deutschmann und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Division of General Gynecology and Gynecologic Oncology, Medical University of Vienna, Waehringer Guertel 18…. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: The introduction of biomarker-guided therapies, including PI3K, AKT and PARP inhibitors as well as Selective Estrogen Receptor Degraders (SERDs), has expanded treatment options and delayed the need for chemotherapy in hormone receptor positive (HR+)/human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC). Nevertheless, evidence regarding their implementation in routine clinical practice remains limited. This study evaluated the real-world use of molecular testing and biomarker-guided therapies in patients with HR+/HER2− mBC.

Methods

Patients with HR+/HER2− mBC treated at the Medical University of Vienna, Austria, between July 2020 (EMA approval of alpelisib, marking the introduction of biomarker-guided therapies in HR+/HER2− mBC) and April 2025 were identified through a retrospective chart review. Patient and disease characteristics, molecular testing patterns, utilization of biomarker-guided therapies, and oncological outcome were assessed. Biomarker-guided therapies included alpelisib and capivasertib for PI3K/AKT pathway alterations, elacestrant for ESR1 mutations, and PARP inhibitors for BRCA1/2 mutations. Descriptive statistics summarized patient characteristics, molecular testing, and biomarker-guided therapies. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and prognostic factors were evaluated using univariable and multivariable Cox regression analyses.

Results

A total of 274 patients with HR+/HER2− mBC were included. 63.5% (174/274) of patients had undergone at least one molecular test. Overall, 59.8% (104/174) of patients harbored at least one actionable molecular alteration. Of these, 54.8% (57/104) received a biomarker-matched therapy. Of the 47 patients who had not received a matched therapy, 25 remained on first-line CDK4/6 inhibitor-based treatment and were therefore not yet candidates for subsequent biomarker-guided therapy. 12.8% (6/47) of patients with a targetable alteration did not receive a biomarker-matched therapy but transitioned to chemotherapy or an ADC. Concurrent actionable alterations were uncommon. Among 12 patients with concurrent PI3K/AKT pathway and ESR1 alterations, four received PI3K/AKT-directed therapy only and three ESR1-directed therapy only. Among four patients with concurrent PI3K/AKT pathway and BRCA1/2 alterations, three received PI3K/AKT-directed therapy only, whereas none received a PARP inhibitor. No patient with concurrent actionable alterations in different pathways received more than one biomarker-matched therapy sequentially. Biomarker-guided therapies achieved median treatment durations ranging from 3.5 to 14.5 months and postponed the need for chemotherapy or antibody-drug conjugates (ADCs) by a median of 9 months.

Conclusions

Molecular testing was implemented in a substantial proportion of patients with HR+/HER2− mBC and identified actionable alterations in the majority of tested patients. The use of biomarker-guided therapies delayed treatment escalation to chemotherapy or ADCs.

Schlagwörter

Stichwörter der Autor:innen

BRCA1/2 mutationESR1 mutationHR+/HER2− metastatic breast cancerPI3K/AKT pathway alterationbiomarker-guided therapymolecular testing

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Division of General Gynecology and Gynecologic Oncology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
  • Department of Pathology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.

ORCID-Profile: Leonhard Müllauer, Carmen Leser, Christian F Singer

Zitieren

APA

Deutschmann, C., Filipovic, M., Baha, D., Müllauer, L., Bago-Horvath, Z., Gschwantler-Kaulich, D., Pfeiler, G., Leser, C., & Singer, C. F. (2026). Real-World Implementation of Molecular Testing and Biomarker-Guided Therapies in HR+/HER2− Metastatic Breast Cancer. Cancers, 18(21), 3482. https://doi.org/10.3390/cancers18213482

Vancouver

Deutschmann C, Filipovic M, Baha D, Müllauer L, Bago-Horvath Z, Gschwantler-Kaulich D, et al. Real-World Implementation of Molecular Testing and Biomarker-Guided Therapies in HR+/HER2− Metastatic Breast Cancer. Cancers. 2026;18(21):3482. doi:10.3390/cancers18213482

BibTeX
@article{Deutschmann2026,
  author = {Deutschmann, Christine and Filipovic, Matthias and Baha, Dagmar and Müllauer, Leonhard and Bago-Horvath, Zsuzsanna and Gschwantler-Kaulich, Daphne and Pfeiler, Georg and Leser, Carmen and Singer, Christian F},
  title = {Real-World Implementation of Molecular Testing and Biomarker-Guided Therapies in HR+/HER2− Metastatic Breast Cancer},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {21},
  pages = {3482},
  doi = {10.3390/cancers18213482}
}
Kostenlos starten →